Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2808f5779912ea7fdb826981e34ce015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05fa5732305cc4e8d6ce725614b2f09d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff3fa55d001018392724d04f9a7b40fd |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-28 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0607 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0605 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-44 |
filingDate |
2013-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3b1169b5da91629435bc0fd82b7349d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a418638aedb5151355d4d3ef7d266761 |
publicationDate |
2014-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2014037596-A1 |
titleOfInvention |
Use of Stem Cells to Reduce Leukocyte Extravasation |
abstract |
The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021216580-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10758570-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10967006-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11071752-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9861660-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10253297-B2 |
priorityDate |
2009-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |